Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1373Observational 422Expanded_access 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 14Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Carcinoma, Non-Small-Cell Lung 7Stomach Neoplasms 6Ovarian Neoplasms 6Liver Neoplasms 6Cholangiocarcinoma 6Prostatic Neoplasms 5Breast Neoplasms 5Melanoma 4Sarcoma 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Squamous Cell 3Neuroblastoma 2Neoplasms 2Hepatoblastoma 2Glioblastoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Wounds and Injuries 1Wilms Tumor 1Uveal Melanoma 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Esophageal Neoplasms × Gastrointestinal × Clear all
NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04681248 2025-08-03

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Leap Therapeutics, Inc.

No longer available
GastrointestinalGynecologicSarcoma

Carcinoma, Squamous Cell, Carcinosarcoma, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡